<?xml version='1.0' encoding='utf-8'?>
<document id="29759903"><sentence text="Potential Adverse Drug Events and Nephrotoxicity Related to Prophylaxis With Omeprazole for Digestive Disorders: A Prospective Cohort Study."><entity charOffset="77-87" id="DDI-PubMed.29759903.s1.e0" text="Omeprazole" /></sentence><sentence text="The purpose of this study was to assess whether prophylaxis for digestive disorders with omeprazole is a risk factor for adverse drug events (ADEs) and kidney impairment"><entity charOffset="89-99" id="DDI-PubMed.29759903.s2.e0" text="omeprazole" /></sentence><sentence text="" /><sentence text="This was a 9-month, prospective, double-blinded cohort study performed in a Brazilian public hospital" /><sentence text=" All inpatients 18 years or older admitted during the period of data collection were divided into 2 cohorts" /><sentence text=" The first group comprised 200 patients receiving prophylaxis for digestive disorders with omeprazole"><entity charOffset="91-101" id="DDI-PubMed.29759903.s6.e0" text="omeprazole" /></sentence><sentence text=" A total of 54 inpatients who received treatment with omeprazole and whose indication was not approved by the Brazilian Sanitary Agency and the US Food and Drug Administration were excluded"><entity charOffset="54-64" id="DDI-PubMed.29759903.s7.e0" text="omeprazole" /></sentence><sentence text=" The second group comprised 219 inpatients without a prescription for omeprazole"><entity charOffset="70-80" id="DDI-PubMed.29759903.s8.e0" text="omeprazole" /></sentence><sentence text=" Follow-up was performed until discharge and included assessment of medical records, medical prescriptions, laboratory data, and pharmaceutical anamnesis" /><sentence text=" The primary end point was kidney impairment" /><sentence text=" The variables monitored were kidney function (serum creatinine and urea levels as well as glomerular filtration rate), hepatic function (alanine aminotransferase and aspartate aminotransferase levels), pharmacotherapy, magnesium levels, and imputation of ADEs"><entity charOffset="53-63" id="DDI-PubMed.29759903.s11.e0" text="creatinine" /><entity charOffset="68-72" id="DDI-PubMed.29759903.s11.e1" text="urea" /><entity charOffset="138-145" id="DDI-PubMed.29759903.s11.e2" text="alanine" /><entity charOffset="167-176" id="DDI-PubMed.29759903.s11.e3" text="aspartate" /><entity charOffset="220-229" id="DDI-PubMed.29759903.s11.e4" text="magnesium" /><pair ddi="false" e1="DDI-PubMed.29759903.s11.e0" e2="DDI-PubMed.29759903.s11.e0" /><pair ddi="false" e1="DDI-PubMed.29759903.s11.e0" e2="DDI-PubMed.29759903.s11.e1" /><pair ddi="false" e1="DDI-PubMed.29759903.s11.e0" e2="DDI-PubMed.29759903.s11.e2" /><pair ddi="false" e1="DDI-PubMed.29759903.s11.e0" e2="DDI-PubMed.29759903.s11.e3" /><pair ddi="false" e1="DDI-PubMed.29759903.s11.e0" e2="DDI-PubMed.29759903.s11.e4" /><pair ddi="false" e1="DDI-PubMed.29759903.s11.e1" e2="DDI-PubMed.29759903.s11.e1" /><pair ddi="false" e1="DDI-PubMed.29759903.s11.e1" e2="DDI-PubMed.29759903.s11.e2" /><pair ddi="false" e1="DDI-PubMed.29759903.s11.e1" e2="DDI-PubMed.29759903.s11.e3" /><pair ddi="false" e1="DDI-PubMed.29759903.s11.e1" e2="DDI-PubMed.29759903.s11.e4" /><pair ddi="false" e1="DDI-PubMed.29759903.s11.e2" e2="DDI-PubMed.29759903.s11.e2" /><pair ddi="false" e1="DDI-PubMed.29759903.s11.e2" e2="DDI-PubMed.29759903.s11.e3" /><pair ddi="false" e1="DDI-PubMed.29759903.s11.e2" e2="DDI-PubMed.29759903.s11.e4" /><pair ddi="false" e1="DDI-PubMed.29759903.s11.e3" e2="DDI-PubMed.29759903.s11.e3" /><pair ddi="false" e1="DDI-PubMed.29759903.s11.e3" e2="DDI-PubMed.29759903.s11.e4" /></sentence><sentence text=" With the aid of algorithms of World Health Organization and the National Coordinating Council for Medication Error Reporting and Prevention, we assessed the causality of adverse drug reactions (ADRs) and the seriousness of medication errors (ADEs), respectively" /><sentence text="" /><sentence text="Prophylaxis for digestive disorders with omeprazole (P = 0"><entity charOffset="41-51" id="DDI-PubMed.29759903.s14.e0" text="omeprazole" /></sentence><sentence text="019) and sex (P = 0" /><sentence text="010) were considered risk factors for increased serum creatinine level via multivariate logistic regression even with concomitant use of nephrotoxic drugs (P = 0"><entity charOffset="54-64" id="DDI-PubMed.29759903.s16.e0" text="creatinine" /></sentence><sentence text="252)" /><sentence text=" Six ADEs related to omeprazole were identified: 2 ADRs (1 possible and 1 definite), 2 medication errors (nonserious), 1 therapeutic failure, and 1 drug-drug interaction"><entity charOffset="21-31" id="DDI-PubMed.29759903.s18.e0" text="omeprazole" /></sentence><sentence text="" /><sentence text="Prophylaxis for digestive disorders with omeprazole and male sex may contribute to the development of kidney impairment because both result in increased serum creatinine levels"><entity charOffset="41-51" id="DDI-PubMed.29759903.s20.e0" text="omeprazole" /><entity charOffset="159-169" id="DDI-PubMed.29759903.s20.e1" text="creatinine" /><pair ddi="false" e1="DDI-PubMed.29759903.s20.e0" e2="DDI-PubMed.29759903.s20.e0" /><pair ddi="false" e1="DDI-PubMed.29759903.s20.e0" e2="DDI-PubMed.29759903.s20.e1" /></sentence><sentence text=" Therefore, pharmacotherapeutic follow-up of male patients diagnosed with kidney disorders should be considered to identify potential drug-drug interactions early" /><sentence text=" This follow-up can prevent worsening clinical conditions and/or contraindicate prophylactic use of omeprazole"><entity charOffset="100-110" id="DDI-PubMed.29759903.s22.e0" text="omeprazole" /></sentence><sentence text=" ClinicalTrials" /><sentence text="gov identifier: NCT02278432" /><sentence text="" /></document>